Related Experiment Videos
Novel HDAC inhibitors with radiosensitizing properties.
Mira Jung1, Alfredo Velena, Bin Chen
1Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057, USA. jungm@georgetown.edu
Radiation Research
|April 27, 2005
Summary
Researchers designed novel histone deacetylase (HDAC) inhibitors. Six compounds showed nanomolar potency and inhibited cancer cell proliferation, demonstrating potential as radiosensitizing agents for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Histone deacetylases (HDACs) regulate critical cellular processes like proliferation and apoptosis.
- HDAC inhibitors are a promising class of chemotherapeutic agents.
- Targeting HDACs offers potential for cancer treatment and radiosensitization.
Purpose of the Study:
- To design and identify novel, potent, and stable HDAC inhibitors.
- To evaluate the efficacy of these inhibitors in sensitizing cancer cells to radiation therapy.
- To explore the translational potential of these compounds in clinical applications.
Main Methods:
- Rational drug design of over 60 HDAC inhibitor analogues.
- Incorporation of a urea backbone and hydroxamic acid end moiety.
- Screening for enzyme inhibition, antiproliferative activity, and radiosensitizing properties.
Main Results:
- Six novel HDAC inhibitors achieved 50% enzyme inhibition at nanomolar concentrations.
- Candidate inhibitors demonstrated IC50 values of 10-50 microM against prostate, breast, and head and neck cancer cells.
- Compounds exhibited cell type-specific radiosensitizing effects in clonogenic survival assays.
Conclusions:
- The designed HDAC inhibitors exhibit potent enzyme inhibitory and antiproliferative activities.
- These compounds show promise as radiosensitizing agents for specific cancer types.
- Further investigation is warranted for potential clinical application in combination cancer therapy.